Autism 27, 117132
While this study population was specific, the magnitude of weight loss aligns with and extends the Phase 2 findings, suggesting that the 24% range is reproducible across populations at the highest dose
A strong product will need to help people navigate coverage changes, medication transitions and maintenance plans without assuming the insurer will keep paying
To move Epitalon from experimental to evidence-based, several developments are essential: Randomized, double-blind, placebo-controlled clinical trials, ideally targeting specific endpoints (sleep, immune aging, telomere attrition) Toxicology and long-term safety studies, including exploration of stereoisomer effects and off-target consequences Validated delivery systems (e.g., dendrimer-conjugates, transdermal patches) that make real-world use feasible Pharmacodynamic biomarkers, to identify responders and track efficacy objectively over time Epitalon is not snake oil, but its also not a magic bullet
It is important to appreciate, however, that the increased risk relates to a disorder that is relatively uncommon. NAION is rare, affecting up to 10 out of 100,000 people in the general population
Beta-glucans are the soluble part of dietary fiber found in the cell wall of fungi, yeast, algae, and cereals 1
